Interview with Andrew Giddy, CEO, Nucleus Network
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
Address: 5th Floor, Burnet Tower, AMREP Precinct ,89 Commercial Road,Melbourne, Victoria, Australia, 3004
Tel: + 613 9076 8900
Web: http://www.nucleusnetwork.com.au/page.aspx?54
Nucleus Network is committed to operational and service excellence. All Nucleus Network’s clinical research is conducted in accordance with internationallyrecognised standards of Good Clinical Practice. Data generated is accepted by all major regulatory jurisdictions including FDA, EMEA and TGA.
Whether you work with Nucleus Network clinical research team, education or consulting personnel, Nucleus Network are committed to providing high quality services and adherence to ethical principles. It is Nucleus Network’s aim to deliver services in a timely and cost-effective manner and to give customers peace of mind. To achieve this, Nucleus Network uses the latest technologies within a coordinated and collaborative framework.
Nucleus Network is committed to quality and continuous improvement in order to meet our clients’ needs for timeliness and high quality data.
Research, Clinical trials
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Would you please introduce The Pharmacy Guild to our readers, giving an insight in its function and its membership? We are the premium body representing community pharmacies in Australia, about…
Earlier this year the company set a crucial step in its internationalization strategy with the acquisition of Ascent. Would you outline the significance of the acquisition within Watson’s global expansion…
We last met you in 2008 as Chair of the Pharmaceuticals Industry Council (PIC), which set itself the goal of doubling the levels of exports, R&D investment, manufacturing, value-added activities,…
Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike…
You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine,…
In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We…
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
See our Cookie Privacy Policy Here
